Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) insider Mark Andrew Wilson sold 33,402 shares of Nektar Therapeutics stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $0.90, for a total transaction of $30,061.80. Following the transaction, the insider now owns 351,892 shares of the company's stock, valued at approximately $316,702.80. The trade was a 8.67 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Nektar Therapeutics Stock Performance
NKTR stock opened at $0.95 on Friday. The company has a 50 day moving average price of $1.14 and a two-hundred day moving average price of $1.22. The stock has a market capitalization of $175.46 million, a P/E ratio of -1.13 and a beta of 0.57. Nektar Therapeutics has a one year low of $0.48 and a one year high of $1.93.
Analysts Set New Price Targets
A number of research analysts have recently weighed in on the stock. BTIG Research reissued a "buy" rating and set a $4.00 price objective on shares of Nektar Therapeutics in a research note on Monday, September 30th. Piper Sandler started coverage on Nektar Therapeutics in a research report on Monday, November 4th. They set an "overweight" rating and a $7.00 price target for the company. Finally, HC Wainwright assumed coverage on Nektar Therapeutics in a research report on Tuesday, December 10th. They issued a "buy" rating and a $6.50 price objective on the stock. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $4.10.
#1 Crypto of 2025
From True Market Insiders | Ad
Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017…
And has spotted 44 different coins that have returned over 100%...
But today, Chris is now making the biggest crypto call of his ENTIRE career…
#1 FREE Crypto for 2025
Read Our Latest Research Report on Nektar Therapeutics
Institutional Investors Weigh In On Nektar Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the business. Samlyn Capital LLC purchased a new position in Nektar Therapeutics during the second quarter worth about $11,728,000. Eventide Asset Management LLC increased its stake in shares of Nektar Therapeutics by 24.8% during the 3rd quarter. Eventide Asset Management LLC now owns 9,400,000 shares of the biopharmaceutical company's stock valued at $12,220,000 after acquiring an additional 1,870,904 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Nektar Therapeutics by 56.1% during the 2nd quarter. Millennium Management LLC now owns 4,659,469 shares of the biopharmaceutical company's stock worth $5,778,000 after acquiring an additional 1,674,924 shares during the period. Nantahala Capital Management LLC raised its stake in Nektar Therapeutics by 66.0% during the second quarter. Nantahala Capital Management LLC now owns 4,110,000 shares of the biopharmaceutical company's stock worth $5,096,000 after purchasing an additional 1,634,046 shares during the period. Finally, State Street Corp raised its position in shares of Nektar Therapeutics by 11.9% in the 3rd quarter. State Street Corp now owns 3,345,733 shares of the biopharmaceutical company's stock worth $4,349,000 after buying an additional 355,759 shares during the period. Hedge funds and other institutional investors own 75.88% of the company's stock.
Nektar Therapeutics Company Profile
(
Get Free Report)
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
